Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

Cantor Fitzgerald analyst Kristen Kluska has maintained an Overweight rating on Celldex Therapeutics (NASDAQ: CLDX) and raised the price target from $61 to $72.